OrbiMed Advisors

OrbiMed Buys $30M of Braveheart Bio (BRVE) Stock

by
SEC Form 4 filing details showing OrbiMed Advisors LLC's purchase of Braveheart Bio (BRVE) shares

OrbiMed Advisors LLC, a director and 10%-plus owner of Braveheart Bio, Inc. (BRVE), disclosed an open-market purchase of 1,666,667 shares at $18.00 apiece, a cash outlay of $30,000,006.00, according to a Form 4 filed with the SEC. The transaction is dated August 7, 2026, and brings OrbiMed’s indirectly held stake to 11,901,826 shares. The purchase … Read more

SCTX Insider Buy: OrbiMed Director Buys $15M in Shares

by
Chart showing OrbiMed Advisors' $15 million open-market purchase of Scribe Therapeutics (SCTX) shares

Insider trading today includes a notable open-market purchase at Scribe Therapeutics, Inc. (SCTX). A Form 4 filing shows OrbiMed Advisors LLC, listed as a director of the gene-editing company, bought 1,000,000 shares on July 27, 2026, at $15.00 per share for a total outlay of $15,000,000. The transaction was an open-market buy, meaning OrbiMed used … Read more